clinical trial · NCT04976322
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
UCB Biopharma SRL·phase3·enrolling by invitation·n = 760
Systemic Lupus ErythematosusDapirolizumab pegol
brief summary
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
started
Jul 27, 2021
primary completion
Aug 7, 2030
completion
Aug 7, 2030
last updated
Jun 12, 2026
official title
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol